Sign in or create an account to add this stock to your watchlist.
About Mersana Therapeutics (NASDAQ:MRSN)
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The company develops Dolaflexin, an antibody drug conjugate (ADC) platform designed to enhance the potency and efficacy of ADCs while simultaneously enhancing the safety and tolerability. Its lead product candidates include XMT-1522, an ADC targeting HER2-expressing tumors, which is in Phase I clinical trial for treating patients with breast cancer, non-small-cell-lung-cancer (NSCLC), and gastric cancer; and XMT-1536, an ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, NSCLC, and other cancers. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck KGaA; and Asana BioSciences, LLC. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2002 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MRSN
CUSIPN/A
Phone617-498-0020
Debt
Debt-to-Equity RatioN/A
Current Ratio3.80
Quick Ratio3.80
Price-To-Earnings
Trailing P/E Ratio-5.95
Forward P/E Ratio-8.15
P/E GrowthN/A
Sales & Book Value
Annual Sales$17.55 million
Price / Sales25.00
Cash FlowN/A
Price / CashN/A
Book Value$3.08 per share
Price / Book6.22
Profitability
EPS (Most Recent Fiscal Year)($3.22)
Net Income$-38,700,000.00
Net Margins-263.80%
Return on Equity-124.32%
Return on Assets-36.28%
Miscellaneous
Employees78
Outstanding Shares22,900,000
Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions
What is Mersana Therapeutics' stock symbol?
Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."
How were Mersana Therapeutics' earnings last quarter?
Mersana Therapeutics Inc. (NASDAQ:MRSN) announced its quarterly earnings results on Monday, May, 14th. The company reported ($0.54) earnings per share for the quarter, topping analysts' consensus estimates of ($0.61) by $0.07. The firm had revenue of $3.06 million for the quarter, compared to the consensus estimate of $3.49 million. Mersana Therapeutics had a negative return on equity of 124.32% and a negative net margin of 263.80%. View Mersana Therapeutics' Earnings History.
What price target have analysts set for MRSN?
6 brokerages have issued twelve-month price objectives for Mersana Therapeutics' shares. Their forecasts range from $23.00 to $33.00. On average, they anticipate Mersana Therapeutics' share price to reach $26.80 in the next twelve months. View Analyst Ratings for Mersana Therapeutics.
Who are some of Mersana Therapeutics' key competitors?
Some companies that are related to Mersana Therapeutics include G1 Therapeutics (GTHX), Cambrex (CBM), ARMO BioSciences (ARMO), PTC Therapeutics (PTCT), Innoviva (INVA), Zogenix (ZGNX), Radius Health (RDUS), Pacira Pharmaceuticals (PCRX), ImmunoGen (IMGN), Apellis Pharmaceuticals (APLS), Endo International (ENDP), TherapeuticsMD (TXMD), Impax Laboratories (IPXL), Theravance Biopharma (TBPH) and Myovant Sciences (MYOV).
Who are Mersana Therapeutics' key executives?
Mersana Therapeutics' management team includes the folowing people:
- Mr. David M. Mott, Exec. Chairman (Age 53)
- Ms. Anna Protopapas, Pres, CEO & Director (Age 54)
- Dr. Timothy B. Lowinger Ph.D., Sr. VP & Chief Scientific Officer (Age 54)
- Dr. Donald A. Bergstrom, Former Sr. VP & Chief Medical Officer (Age 46)
- Mr. Mikhail Papisov Ph.D., Co-Founder
When did Mersana Therapeutics IPO?
(MRSN) raised $75 million in an IPO on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Has Mersana Therapeutics been receiving favorable news coverage?
News headlines about MRSN stock have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mersana Therapeutics earned a news sentiment score of 0.14 on Accern's scale. They also assigned media coverage about the company an impact score of 47.81 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Mersana Therapeutics' major shareholders?
Mersana Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Rock Springs Capital Management LP (5.69%), BlackRock Inc. (3.58%), RHO Capital Partners Inc. (3.49%), JPMorgan Chase & Co. (1.35%), Point72 Asset Management L.P. (0.74%) and Northern Trust Corp (0.49%). View Institutional Ownership Trends for Mersana Therapeutics.
Which major investors are selling Mersana Therapeutics stock?
MRSN stock was sold by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, JPMorgan Chase & Co., RHO Capital Partners Inc., Allianz Asset Management GmbH and DekaBank Deutsche Girozentrale. View Insider Buying and Selling for Mersana Therapeutics.
Which major investors are buying Mersana Therapeutics stock?
MRSN stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Point72 Asset Management L.P., Northern Trust Corp, Russell Investments Group Ltd., Candriam Luxembourg S.C.A., Schwab Charles Investment Management Inc., Stanley Laman Group Ltd. and Quantitative Systematic Strategies LLC. View Insider Buying and Selling for Mersana Therapeutics.
How do I buy shares of Mersana Therapeutics?
Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mersana Therapeutics' stock price today?
One share of MRSN stock can currently be purchased for approximately $19.16.
How big of a company is Mersana Therapeutics?
Mersana Therapeutics has a market capitalization of $435.36 million and generates $17.55 million in revenue each year. The company earns $-38,700,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Mersana Therapeutics employs 78 workers across the globe.
How can I contact Mersana Therapeutics?
Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]
MarketBeat Community Rating for Mersana Therapeutics (MRSN)
MarketBeat's community ratings are surveys of what our community members think about Mersana Therapeutics and other stocks. Vote "Outperform" if you believe MRSN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRSN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Mersana Therapeutics (NASDAQ:MRSN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Mersana Therapeutics in the last 12 months. Their average twelve-month price target is $26.80, suggesting that the stock has a possible upside of 39.87%. The high price target for MRSN is $33.00 and the low price target for MRSN is $23.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.83 | 2.80 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $26.80 | $26.00 | $23.6667 | $23.6667 |
| Price Target Upside: | 39.87% upside | 52.85% upside | 54.48% upside | 68.45% upside |
Mersana Therapeutics (NASDAQ:MRSN) Consensus Price Target History
Mersana Therapeutics (NASDAQ:MRSN) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
Mersana Therapeutics (NASDAQ:MRSN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Mersana Therapeutics (NASDAQ MRSN) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 81.86%
Mersana Therapeutics (NASDAQ MRSN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 7/3/2017 | M James Barrett | Major Shareholder | Buy | 1,000,000 | $15.00 | $15,000,000.00 | |  |
(Data available from 1/1/2013 forward)
Mersana Therapeutics (NASDAQ MRSN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Wedbush Analysts Lift Earnings Estimates for Mersana Therapeutics Inc. (MRSN)
www.americanbankingnews.com - May 17 at 6:35 AM |
| Q2 2018 EPS Estimates for Mersana Therapeutics Inc. Lifted by Analyst (MRSN)
www.americanbankingnews.com - May 17 at 6:35 AM |
| HC Wainwright Analysts Give Mersana Therapeutics (MRSN) a $33.00 Price Target
www.americanbankingnews.com - May 15 at 1:13 PM |
 | Mersana Therapeutics beats by $0.07, misses on revenue
seekingalpha.com - May 15 at 10:05 AM |
| Mersana Therapeutics' (MRSN) CEO Anna Protopapas on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 15 at 10:05 AM |
| Mersana Therapeutics (MRSN) Posts Earnings Results, Beats Estimates By $0.07 EPS
www.americanbankingnews.com - May 15 at 7:35 AM |
 | Mersana Therapeutics Announces First Quarter 2018 Financial Results and Provides Business Updates
finance.yahoo.com - May 14 at 4:25 PM |
| $3.49 Million in Sales Expected for Mersana Therapeutics Inc. (MRSN) This Quarter
www.americanbankingnews.com - May 14 at 4:00 AM |
| Mersana Therapeutics Inc. (MRSN) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 13 at 1:39 AM |
| Mersana Therapeutics Inc. (MRSN) Expected to Announce Earnings of -$0.61 Per Share
www.americanbankingnews.com - May 12 at 12:03 PM |
| Baird: Mersana Is A Buy On Differentiated Platform For Cancer Indications
finance.yahoo.com - May 8 at 4:24 PM |
| Mersana Therapeutics (MRSN) Now Covered by Analysts at Robert W. Baird
www.americanbankingnews.com - May 7 at 5:28 PM |
| Mersana Therapeutics to Host Conference Call Announcing First Quarter 2018 Financial Results and Business Updates
finance.yahoo.com - May 7 at 4:33 PM |
| Mersana Therapeutics (MRSN) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - May 2 at 11:38 PM |
| Mersana Therapeutics to Present at the Deutsche Bank 43rd Annual Health Care Conference
finance.yahoo.com - May 1 at 4:20 PM |
| Mersana Therapeutics Inc. (MRSN) Expected to Announce Quarterly Sales of $3.36 Million
www.americanbankingnews.com - April 26 at 1:06 AM |
| Mersana Therapeutics (MRSN) PT Set at $33.00 by HC Wainwright
www.americanbankingnews.com - April 25 at 9:58 AM |
| -$0.61 EPS Expected for Mersana Therapeutics Inc. (MRSN) This Quarter
www.americanbankingnews.com - April 24 at 11:22 PM |
| Wired News – European Medicines Agency Granted Orphan Drug Designation for Abeona’s ABO-202 Gene Therapy Program in Batten Disease
finance.yahoo.com - April 24 at 9:31 AM |
| Wired News - Krystal Biotech's Lead Product Candidate, KB103, for Treatment of DEB Receives Orphan Medicinal Product Designation in Europe
finance.yahoo.com - April 23 at 9:14 AM |
 | Mersana Therapeutics (MRSN) Announces New Preclinical Data on Lead ADC Platform Dolaflexin & HER2 Targeted ADC XMT-1522
www.streetinsider.com - April 18 at 4:38 PM |
| Mersana Therapeutics (MRSN) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - April 18 at 9:00 AM |
| Mersana Therapeutics (MRSN) Given a $33.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 18 at 8:36 AM |
| Mersana Therapeutics Inc. (MRSN) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 18 at 1:30 AM |
| Mersana Therapeutics Presents Preclinical Data Further Demonstrating Differentiating Aspects of Its ADC Platform Technology at AACR 2018
finance.yahoo.com - April 17 at 4:47 PM |
| Mersana Therapeutics (MRSN) Coverage Initiated by Analysts at Leerink Swann
www.americanbankingnews.com - April 16 at 10:22 PM |
| Mersana Therapeutics (MRSN) Research Coverage Started at JPMorgan Chase
www.americanbankingnews.com - April 16 at 10:22 PM |
| Cowen Begins Coverage on Mersana Therapeutics (MRSN)
www.americanbankingnews.com - April 16 at 10:22 PM |
| Mersana Therapeutics (MRSN) Stock Rating Reaffirmed by Cowen
www.americanbankingnews.com - April 16 at 4:16 PM |
| Mersana Therapeutics (MRSN) Announces Poster Presentations Demonstrating Differentiating Aspects of ADC Platform Technology at AACR
www.streetinsider.com - April 10 at 9:58 AM |
| Mersana Therapeutics Announces Poster Presentations Demonstrating Differentiating Aspects of ADC Platform Technology at the American Association for Cancer Research Annual Meeting 2018
finance.yahoo.com - April 9 at 9:48 AM |
| $3.36 Million in Sales Expected for Mersana Therapeutics Inc. (MRSN) This Quarter
www.americanbankingnews.com - April 9 at 1:05 AM |
| Zacks: Analysts Anticipate Mersana Therapeutics Inc. (MRSN) Will Post Earnings of -$0.61 Per Share
www.americanbankingnews.com - April 7 at 11:10 PM |
| Mersana Therapeutics (MRSN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 7 at 9:29 AM |
| Mersana Therapeutics Inc’s (NASDAQ:MRSN) Profit Outlook
finance.yahoo.com - April 4 at 5:08 PM |
| Mersana Therapeutics' (MRSN) "Outperform" Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - April 3 at 7:48 AM |
| Mersana Therapeutics (MRSN) Announces Earnings Results
www.americanbankingnews.com - March 29 at 7:38 AM |
| Mersana Therapeutics (MRSN) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - March 29 at 12:34 AM |
| Mersana Therapeutics misses by $0.11, misses on revenue
seekingalpha.com - March 28 at 9:48 AM |
| Mersana Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates
finance.yahoo.com - March 28 at 9:48 AM |
| Does Mersana Therapeutics Inc’s (NASDAQ:MRSN) Past Performance Indicate A Weaker Future?
finance.yahoo.com - March 27 at 10:03 AM |
| $4.22 Million in Sales Expected for Mersana Therapeutics Inc. (MRSN) This Quarter
www.americanbankingnews.com - March 24 at 9:12 AM |
| Mersana Therapeutics Inc. (MRSN) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 24 at 1:44 AM |
| Mersana Therapeutics (MRSN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 23 at 10:46 PM |
| Zacks Investment Research Lowers Mersana Therapeutics (MRSN) to Hold
www.americanbankingnews.com - March 23 at 7:22 PM |
| Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Full Year 2017 Financial Results and Business Updates
finance.yahoo.com - March 21 at 4:20 PM |
| Eeny, Meeny, Miny, Moe: JPMorgan Downgrades 4 Biotechs In Portfolio Rebalancing
finance.yahoo.com - March 19 at 4:17 PM |
| Mersana Therapeutics (MRSN) Downgraded by JPMorgan Chase & Co.
www.americanbankingnews.com - March 19 at 10:58 AM |
| Mersana Strengthens Board of Directors Leadership with Appointment of Willard H. Dere, M.D., Professor at the University of Utah and Retired Chief Medical Officer of Amgen
finance.yahoo.com - March 19 at 9:44 AM |
| Mersana Appoints David A. Spellman as Chief Financial Officer
finance.yahoo.com - March 12 at 10:48 AM |
Mersana Therapeutics (NASDAQ:MRSN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Mersana Therapeutics (NASDAQ:MRSN) Income Statement, Balance Sheet and Cash Flow Statement
Mersana Therapeutics (NASDAQ MRSN) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
